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Background: Whereas the cost burden of healthcare-associated infection (HAI) extends
beyond the inpatient stay into the post-discharge period, few studies have focused on post-
discharge costs.
Aim: To investigate the impact of all types of HAI on the magnitude and distribution of
post-discharge costs observed in acute and community services for patients who devel-
oped HAI during their inpatient stay.
Methods: Using data from the Evaluation of Cost of Nosocomial Infection (ECONI) study
and regression methods, this study identifies the marginal effect of HAI on the 90-daypost-
discharge resource use and costs. To calculate monetary values, unit costs were applied to
estimates of excess resource use per case of HAI.
Findings: Post-discharge costs increase inpatient HAI costs by 36%, with an annual national
cost of £10,832,437. The total extra cost per patient with HAI was £1,457 (95% confidence
interval: 1,004e4,244) in the 90 days post discharge. Patients with HAI had longer LOS if they
were readmitted and were prescribed more antibiotics in the community. The results suggest
that HAI did not have an impact on the number of readmissions or repeat surgeries within 90
days of discharge. The majority (95%) of the excess costs was on acute care services after
readmission. Bloodstream infection, gastrointestinal infection, and pneumonia had the big-
gest impact on post-discharge cost.
Conclusion: HAI increases costs and antibiotic consumption in the post-discharge period.
Economic evaluations of IPC studies should incorporate post-discharge costs. Thesealedonian University, Cowcaddens Road, Glasgow G4 0BA, UK. Tel.: þ44 (0)1413 313536.
S. Stewart).
n behalf of The Healthcare Infection Society.
S. Manoukian et al. / Journal of Hospital Infection 114 (2021) 51e5852findings can be used nationally and internationally to support decision-making on the
impact of IPC interventions.
ª 2021 Published by Elsevier Ltd on behalf of The Healthcare Infection Society.Introduction
Healthcare-associated infections (HAIs) increase the cost of
healthcare and impose additional morbidity and risk of mor-
tality [1]. The cost burden extends beyond the inpatient stay
into the post-discharge period, yet a 2005 review showed that
most published studies focus on inpatient costs only, partic-
ularly additional length of stay (LOS), and ignore the post-
discharge period [2]. Previous research has mostly focused on
the post-discharge incidence of surgical site infection (SSI) and
associated costs [3e5]. Reporting post-discharge impact of HAI
requires long-term follow-up of patients with, and without, HAI
once they have left hospital. Recording healthcare utilization
by these patients, which can be resource intensive to collate,
is further complicated by the requirement to adjust for
comorbidities seen within this patient population. The chal-
lenges and variability of estimates have been well described
[6]. Plowman et al. reported similar post-discharge resource
use between HAI and non-HAI groups [7,8]. Other studies have
shown an increase in hospital readmissions in HAI patients
when compared to patients without HAI [9e13]. One review in
the USA estimated that between 9% and 13% of the total health
cost of HAI occurs post discharge and highlighted the
wide range of methodologies, different HAI types, settings and
differences in reporting [14]. These create challenges when
interpreting the findings of the few studies that include a
perspective broader than acute hospitals.
Reliable estimates on the total burden of HAI are critical for
assessing the cost-effectiveness of infection prevention and
control (IPC) programmes [15]. This requires estimates of
resource use incurred during both the inpatient and post-
discharge phases. With a growing focus on minimizing the
duration of hospital stays there is an increasing requirement for
acute and community services to be involved in patient care
after a patient has been discharged from hospital. However,
little is known about the impact of all types of HAI on the level
and distribution of post-discharge resource use among acute
and community services. The aim of this study was to inves-
tigate the impact of all types of HAI on the magnitude and
distribution of post-discharge costs observed in acute and
community services for patients who developed HAI during
their inpatient stay. As such, the study provides information
that can be used in the economic evaluation of IPC measures,
as the financial benefits of preventing HAI in hospital may
extend after the inpatient stay.Methods
The analysis focuses on resource use and resulting costs that
fall directly on the health service in the 90 days after patients
are discharged from hospital. A 90-daypost-discharge period
was chosen to fully capture the impact on resource use that can
be attributed to the preceding hospital stay.Incidence of HAI
The Evaluation of Cost of Nosocomial Infection (ECONI)
study was a two-centre, prospective observational HAI inci-
dence study with record linkage. The study was undertaken in
one Scottish NHS teaching hospital and one general hospital,
which were selected as being broadly representative of other
acute hospitals of their type in Scotland in terms of patient
specialties, HAI prevalence, and patient mix [16]. Data col-
lection began in April 2018 and continued for one calendar
year. All adult inpatients admitted overnight were included
within an incidence cohort. HAI cases were defined using the
ECDC epidemiological case definitions [17,18]. National esti-
mates of incidence are reported elsewhere within each spe-
cialty group and hospital type in 2018/19 [19].Identification of excess post-discharge resource use
All adult overnight admissions to the study hospitals,
including HAI cases and non-cases, were linked to NHS Scotland
administrative electronic databases that contain information
on discharge specialty, reason for admission, post-discharge
episodes of care, post-discharge healthcare contacts, surgical
interventions, and post-admission prescribing [20e23].
During the study there were 99,018 admissions to the
hospitals. This analysis includes 664 patients who developed
HAI and 43,841 patients with no HAI (see Appendix
Figure A1). Patients who did not have a complete 90 days
follow-up were excluded from the analysis. Patients who
died within 90 days post discharge were excluded (2604
people died in hospital including 158 with HAI and 2374
people died post discharge including 57 with HAI). Patients
were also excluded if they did not have any post-discharge
follow-up information available (in total 2631 people 161 of
which had HAI), plus a small number of patients who had
been discharged from hospital for less than 90 days (31
people all non-HAI).
Regression analysis at the patient level was employed to
identify the marginal effect of HAI on post-discharge resource
use also referred to as patient outcomes. Patient outcomes in
this study included readmissions to acute care hospitals, out-
patient visits, community prescribing and general practitioner
(GP) prescribing costs. In the regression analysis, one admission
or index inpatient stay per patient was selected for the analysis
of events during the 90 days post discharge. In this study,
reported excess LOS due to readmission included stay in any
facility such as intensive care unit (ICU) or other ward; the
excess LOS spent in ICUs was also estimated separately [21].
For patients with multiple HAIs within a single admission, the
first identified infection type was used in the analysis by HAI
type. As a robustness check the analysis was repeated to
include patients who did not survive in the 90 days post dis-
charge (see Appendix Table A4).
The regression model controlled for other covariates likely
to explain variation in the outcomes. Covariates were selected
Table I
Costs (£) for each NHS service
Resource Mean unit cost SD: plausible range Distribution for sensitivity analysis Source
Acute care
Bed-day warda 486.40 307.08 Logenormal ISD [26]
Bed-day ICUa 1800.41 310.48 Logenormal ISD [26]
Theatre cost per casea 616.41 676.68 Normal ISD [26]
Outpatient visit 134.00 96.00e160.00 Normal PSSRU [27]
Community care
GP appointment 28.00 22.40e33.60 Normal PSSRU [29]
NHS, National Health Service; SD, standard deviation; ISD, Information Services Division (ISD) Scotland; ICU, intensive care unit; GP, general
practitioner; PSSRU, Personal Social Services Research Unit.
a Unit costs are based on NHS reference (accounting) costs.
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Admission (SPARRA) tool which predicts an individual’s risk of
being admitted to hospital as an emergency inpatient within
the next year [24,25]. The covariates included were: type of
hospital, sex, age, specialty of admission, type of admission
(elective or emergency), Scottish Index of Multiple Deprivation
(SIMD) as an indicator of deprivation, time since last inpatient
procedure, LOS in the two years before admission, and
comorbidities: cancer, cardiovascular disease, chronic renal
failure, and diabetes.Valuation of HAI excess post-discharge resource use
The second step of the analysis was to build a cost model
with parameters that capture events representing extra use of
services. Estimates of the regression model were multiplied by
the unit costs of services to calculate post-discharge costs for
the average individual affected by HAI. Publicly available unit
costs were used as shown in Table I for each patient outcome.
Costs are reported in pounds sterling using 2018 data [26,27].Annual incidence estimate of all HAI
types from ECONI study
[19]
Cohort with HAI cases and controls
Estimated post discharge resource use
for each HAI type
Adjusted for
Charlson index,





of surgeries in year
before index case,




Cost estimate per HAI ca
and cost per case for each HA
Post-discharge NHS resource use
Unit costs
Estimated cost of resource use
Figure 1. How information was calculated and combined in order to
discharge. HAI, healthcare-associated infection; LOS, length of stay; E
Social Services Research Unit; GP, general practitioner; NHS, NationalBed-day unit costs were based on reference costs that
included permanent staff and other direct costs excluding
capital and overhead costs [26]. The bed-day costs considered
in this study are a proxy for the direct cost of providing
healthcare services in the NHS. The cost of repeat surgeries is
the weighted average of theatre costs across teaching and
large general hospitals in NHS Scotland [26]. Outpatient visits
were costed using the Personal Social Services Research Unit
(PSSRU) [27]. The PSSRU also provides estimates for lower and
upper quartiles of the outpatient visit costs and these were
used as a plausible range.
The cost of prescriptions for antibiotic treatment within the
first 90 days after the index admission episode was calculated
from linkage to the Prescribing Information System dataset
[23]. Community prescribing has been reported in terms of
cost, number of items, number of prescriptions and defined
daily dose (DDD) [28]. Since there is currently no routinely
available data set that collects GP visits, the number of pre-
scriptions for an antibiotic was used as a proxy for GP visits.
Cost of GP appointments was based on the PSSRU with a
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estimate cost per case and total cost of HAI within 90 days post
CONI, Evaluation of Cost of Nosocomial Infection; PSSRU, Personal
Health Service.
Table II
Descriptive characteristics of sample
Variable HAI patients Non-HAI patients
(N ¼ 664) (N ¼ 43,841)
Age (years)
<40 49 (7.4%) 7199 (16.4%)
40e49 55 (8.3%) 4493 (10.3%)
50e59 114 (17.2%) 7082 (16.2%)
60e69 111 (16.7%) 8022 (18.3%)
70e79 165 (24.9%) 8808 (20.1%)
>80 170 (25.6%) 8237 (18.8%)
Sex
Female (Yes) 352 (53.0%) 23,338 (53.2%)
SIMD
1 (most deprived) 133 (20.0%) 8449 (19.3%)
2 204 (30.7%) 11,271 (25.7%)
3 118 (17.8%) 8253 (18.8%)
4 90 (13.6%) 7327 (16.7%)
5 (least deprived) 116 (17.5%) 8294 (18.9%)
Unknown 3 (0.5%) 247 (0.6%)
Hospital type
Teaching hospital 607 (91.4%) 30,804 (70.3%)
General hospital 57 (8.6%) 13,037 (29.7%)
Admission type
Emergency admission (Yes) 562 (84.6%) 32,407 (73.9%)
Specialty
Medical 267 (40.2%) 22,501 (51.3%)
Surgical 246 (37.1%) 16,681 (38.1%)
HDU 59 (8.9%) 1128 (2.6%)
ICU 81 (12.2%) 2059 (4.7%)
Obstetricsegynaecology 11 (1.7%) 1472 (3.4%)
Comorbidities
Diabetes (Yes) 101 (15.2%) 3850 (8.8%)
Chronic renal failure (Yes) 177 (26.7%) 4038 (9.2%)
Cardiovascular disease (Yes) 331 (49.9%) 15,882 (36.2%)
Cancer (Yes) 66 (9.9%) 2092 (4.8%)
Last inpatient procedure (days to admission)
None 300 (45.2%) 28,533 (65.1%)
30 104 (15.7%) 1348 (3.1%)
31e90 80 (12.1%) 2185 (5.0%)
91e180 53 (8.0%) 2609 (6.0%)
181 127 (19.1%) 9166 (20.9%)
Total LOS (days) up to 2 years prior to admission
0 235 (35.4%) 27,192 (62.0%)
1e2 61 (9.2%) 4342 (9.9%)
3e7 65 (9.8%) 4710 (10.7%)
8e14 70 (10.5%) 2710 (6.2%)
15e30 86 (13.0%) 2384 (5.4%)
>30 147 (22.1%) 2503 (5.7%)
HAI typea
BSI 96 (14.5%) N/A N/A
GI 98 (14.8%) N/A N/A
LRI 122 (18.4%) N/A N/A
PN 52 (7.8%) N/A N/A
SSI 107 (16.1%) N/A N/A
UTI 161 (24.3%) N/A N/A
Other 28 (4.2%) N/A N/A
HAI, healthcare-associated infection; SIMD, Scottish Index of Multiple
Deprivation; HDU, high-dependency unit; ICU, intensive care unit; LOS,
length of stay; BSI, bloodstream infection; GI, gastrointestinal
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The statistical analysis accounted for the uncertainty in the
unit costs and excess resource use parameters. First, an
empirical distribution was determined by drawing Monte Carlo
samples from logenormal and normal distributions shown in
Table I. Second, a non-parametric bootstrap approach was
used to calculate confidence intervals (CIs) of estimated
resource use. The post-discharge cost of HAI was defined as the
product of vectors of unit costs and excess resource use by HAI
patients. The empirical distributions were combined with the
bootstrapped data to calculate 95% CIs. Finally, the cost for a
case of HAI was multiplied by the annual estimated number of
HAIs in NHS Scotland. Data sources and how these were com-
bined are shown in Figure 1.Results
The final sample included a total of 44,505 patients (see
Appendix Figure A1 for a strobe diagram). A slightly higher
proportion of HAI patients (8% of HAI patients) died in the 90-
daypost-discharge period than non-HAI patients (5% of non-
HAI patients).
The descriptive characteristics of the HAI and non-HAI
patients in the sample are presented in Table II. HAI patients
tended to be older, but the two groups had similar gender
ratios. There was a greater proportion of emergency admis-
sions compared with elective admissions within the HAI group.
The HAI group showed a greater proportion of comorbidities
than the non-HAI group, had more recent inpatient procedures,
and a greater number of days in hospital within the two years
preceding their index admission.
The results of the regression model are presented in
Table III. The coefficients of excess resource use, in Table III,
may be interpreted as the marginal effect of HAI on post-
discharge outcomes. After controlling for covariates, HAI was
associated with an increase in hospital total bed-days of 2.9
days (standard error (SE): 0.3) but not the total number of
readmissions (0.003; SE: 0.04), so patients with HAI when
readmitted stayed for a longer period. There was no difference
in the number of surgeries for patients with HAI compared to
those without HAI (0.000; SE: 0.03). HAI patients showed a
small increase in the number of outpatient visits of 0.371 (SE:
0.97) within 90 days after discharge compared to those without
HAI.
Antibiotic costs during the 90-day period following the index
hospitalization were £12.80 (SE: 2.2) higher for HAI patients
compared to non-HAI patients. HAI patients were prescribed
6.4 DDD more than non-HAI patients. The total number of
prescriptions for antibiotics was 0.27 greater in the HAI group
and the number of dispensed antibiotic items was 0.27 greater
in the HAI group. In the HAI group 41% of patients received an
antibiotic within 90 days of discharge compared with 24% of
non-HAI patients. HAI resulted in an increase in resource use
for each outcome except number of repeat hospitalizationsinfection; LRI, lower respiratory tract infection; PN, pneumonia; SSI,
surgical site infection; UTI, urinary tract infection; N/A, not applicable.
a Patients with multiple HAIs during their stay were assigned to the
HAI type of the first infection.
Table IV
HAI coefficients for 90-day post-discharge length of stay by HAI
type with bias corrected
HAI type Length of total stay
(days)a
95% CIb
Bloodstream infection 5.44 4.36e7.85





Surgical site infection 1.74 0.73e3.90
Urinary tract infection 2.66 1.85e4.37
HAI, healthcare-associated infection; CI, confidence interval.
a Point estimate was reported at a patient level and excludes all
patients with incomplete follow-up. Adjusted for type of hospital, sex,
age, specialty of admission, type of admission (elective or emergency),
Scottish Index of Multiple Deprivation, time since last inpatient pro-
cedure, length of stay in the two years before admission, diagnosis of
cancer, cardiovascular disease, chronic renal failure, and diabetes.
b Bias-corrected 95% CI based on 5000 bootstrap samples.
Table V
Estimated excess post-discharge costs (£) of HAI




Cost of repeat hospital
admissions
1,386.58 781.83e3,754.31
Cost of number of surgeries 0.00 0.00e41.58
Cost of outpatient visits 49.65 28.58e89.09
Subtotal 1,436.23
Community care
Cost of antibiotics 12.80 10.33e23.80




Total cost per patient 1,456.56 1,004.23e4,243.61




Mean excess resource use per HAI patient within 90 days post-
discharge from hospital






No. of readmissions to
hospital
0.003 0.039 0.000e0.078
Length of total stay
(days)c
2.851 0.297 2.518e3.672
Length of stay in ICU
(days)d
0.085 0.039 0.033e0.218
No. of surgeries 0.000 0.029 0.000e0.062
No. of outpatient visitse 0.371 0.097 0.220e0.622
Community care
Daily defined dosesf 6.368 0.686 5.496e8.640
Gross ingredient cost (£) 12.796 2.202 10.328e23.799




HAI, healthcare-associated infection; SE, standard error; CI, con-
fidence interval; ICU, intensive care unit.
a Coefficients in this column represent point estimates. All models
adjusted for type of hospital, sex, age, specialty of admission, type of
admission (elective or emergency), Scottish Index of Multiple Depri-
vation, time since last inpatient procedure, length of stay (LOS) in the
two years before admission, diagnosis of cancer, cardiovascular dis-
ease, chronic renal failure, and diabetes.
b Bias-corrected 95% CI based on 5000 bootstrap samples.
c Total LOS includes stay in any facility such as intensive care, ICU,
high-dependency unit, and other wards.
d LOS in ICU is estimated separately and should not be added to total
LOS.
e An individual can have more than one outpatient attendance on the
same day in the sample.
f This is daily defined doses (DDD) prescribed in the period of analysis,
which may not reflect actual DDD taken.
g One prescription may have more than one item, and each item may
have different quantities of the same drug.
h Calculated from the number of prescription dates per person in
period.
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non-HAI patients.
Based on results in Table III, the total excess LOS of
readmitted HAI patients was the biggest estimated coef-
ficient (2.851) by far. Excess LOS for these readmissions by
HAI type is reported in Table IV. The longest additional LOS
in readmissions was seen in patients with bloodstream
infection (BSI), followed by gastrointestinal infection (GI),
pneumonia, and urinary tract infection (UTI). SSIs and lower
respiratory tract infections had the least impact on post-
discharge LOS.
In Table V, the excess post-discharge costs for patients with
HAI compared to those without HAI are shown. The total extra
cost per patient with HAI was £1,457 (95% CI: 1,004e4,244) in
the 90 days post discharge. The greatest cost was associated
with repeat hospital admissions.Discussion
This is the first nationally representative study in Scotland
to investigate the burden of HAI in the post-discharge period
from an NHS perspective based on whole-hospital incidence.
The results suggest that patients who develop HAI in hospital
have longer LOS if they are readmitted, and they are pre-
scribed more antibiotics in the 90 days post-discharge period
than non-HAI patients. On average HAI patients were pre-
scribed one single additional prescription of antibiotics given
that most antibiotics in the community are prescribed for
between five and seven days. Overall, the results of this study
suggest that 95% of the post-discharge costs associated with
HAI were due to hospital readmissions. These hospital costs are
mainly staff costs associated with the direct cost of patientBased upon 5000 bootstrap samples for the regression estimates and
5000 Monte Carlo simulations of the costs.
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cost associated with HAI in the post-discharge period. The rest
of the post-discharge cost is associated with outpatient
appointments (3.4%).
Based on the total annual numbers of HAI in teaching and
large general hospitals in NHS Scotland (7437 (95% CI:
7021e7849) estimated elsewhere), annual post-discharge costs
equate to approximately £11 million (9.5me14.4m) [19]. During
2018e2019 the total inpatient expenditure in NHS Scotland was
£4.1 billion, making the post-discharge cost of treatmentw0.3%
of the total acute inpatient budget [30]. The direct inpatient
cost due to HAI has been estimated elsewhere to be £30.1 mil-
lion (14.1me74.4m) per year [31]. This means that on average
the post-discharge period increases inpatient costs by 36%.
This study found patterns of community resource use for
patients with HAIs identified in hospital comparable to those
found by Plowman et al. [8]. This study also confirms other
previous findings that HAI burden does not stop during the
inpatient period but continues after hospital discharge [14].
Our results are similar to those of Chopra et al. who showed
that patients with Clostridium difficile infection (CDI) have
5e6 days excess LOS when readmitted [9]. This study shows
that GI, which could have been caused by any pathogenic agent
including CDI, increases LOS in readmissions by w4 days. The
results of this study are also similar to those of Nelson et al.
who showed that patients with HAI caused by meticillin-
resistantStaphylococcus aureus have increased LOS when
readmitted with additional pharmacy costs [13].
The findings of this study have similarities with inpatient
costs reported elsewhere which suggest that BSIs and pneu-
monias are the most burdensome infection types [31]. How-
ever, other infection types seem to have relatively higher costs
in the inpatient period but are less costly in the post-discharge
period. For example, UTIs have been estimated to have zero
excess LOS in the inpatient stay but showed 2.6 days excess LOS
in the post-discharge period [32]. One explanation for this
result may be that some UTI patients are discharged before
their infections are completely treated and display complex
treatment patterns if readmitted. This could also be due to
unobserved patient characteristics that increase the likelihood
of developing HAI but also increase hospital stay in the post-
discharge period, or there might be omitted factors that con-
found the estimated excess LOS due to HAI. SSI has been esti-
mated previously to be a significant burden in the post-
discharge period and has also been estimated to be the third
most costly infection type in the inpatient stage [31,33]. This
study has shown SSI to be one of the least costly infection types
in the post-discharge period. Some very costly SSIs occur after
hospital discharge and these were not included in this study
[34]. Another explanation may be that SSIs in the post-
discharge period consume other types of services such as
community nursing, which was not included.
The limitations of this study must be noted. HAIs presenting
post-discharge and exclusively treated in the community would
not have been identified and would potentially be within the
non-HAI group. Therefore, estimates of this study are likely to
be an underestimate of the true post-discharge cost of HAI.
Patient-level data on community nursing visits were not avail-
able, which means that the burden on community care may
also be an underestimate. Patients who either died in hospital
or in the post-discharge period were excluded. This means that
patients who were seriously unwell were excluded, but theymay have had a different pattern of resource use. The analysis
was repeated, including some of these patients (deceased in
the 90 days post discharge), and the values were found to be
very similar (see Appendix Table A4). The regression model may
not have controlled for every factor that is correlated with
both the propensity to develop HAI and the level of resource
use in the post-discharge period. If that is the case, the esti-
mates of the regression model do not uniquely capture the
marginal impact of HAI but are a composite of HAI and these
uncontrolled factors.
The unit costs in this study are accounting costs, which,
under conditions of spare capacity, may not reflect opportunity
costs (see Manoukian et al. for a discussion of issues around
using opportunity costs [31]). In this study the unit cost of a
bed-day in wards was calculated by excluding more resource-
intensive facilities such as ICUs and high-dependency units.
Some of the excess LOS due to HAI readmissions may have
taken place in these more expensive units. The regression
results suggest that w3% of the total excess LOS due to read-
missions takes place in ICUs. This implies an extra cost of £154
on average associated with readmissions of HAI patients in
ICUs, meaning that the estimated post-discharge cost of HAI
was underestimated. The purpose of this study was to inves-
tigate resource use in the post-discharge period but it is
important to recognize that HAI also affects quality of life.
Quality of life can be measured using quality-adjusted or
disability-adjusted life-years but this was out of scope for this
study. This study did not examine societal costs such as infor-
mal care, loss of income due to work absence, and other per-
sonal costs. These indirect costs are not routinely collected but
may be substantial for some individuals affected by HAI and are
not always visible to policy-makers.
The strengths of this study are its data sources and the
methodology. This study is important because it provides
information on where future IPC resources could be directed to
increase efficiency within the health system. A 10% reduction in
HAI incidence could result in more than 2100 bed-days being
made available by limiting the length of readmission episodes.
It is important to note that the costs reported in this study
cannot be recovered as cash savings if HAI is prevented, but are
valuations of alternative uses such as treating other patients
[15]. These findings indicate that a reduction in HAI cases
would mainly impact acute care rather than community care.
However, patients with HAI had on average one additional
prescription for antibiotics post discharge, and although the
cost of these antibiotics and the associated GP prescribing time
was small, these contribute to the overall burden of community
prescribing, and therein may have secondary unmeasured
impacts such as a higher risk of antimicrobial resistance.
In conclusion, this is the first study for more than 20 years in
the UK to examine the cost of HAI in the post-discharge period.
It presents comprehensive data on all HAI at the facility and
national level. The evidence presented is consistent with
existing literature and shows that HAI increases costs and
antibiotic consumption after discharge. More research is
needed, especially on the post-discharge impact of HAI on
patients and informal carers. Economic evaluations of IPC
studies should incorporate post-discharge costs, including
readmission costs, which may be a substantial proportion of
total costs attributed to HAI. These findings can be used
nationally and internationally to support decision-making on
the impact of IPC interventions.
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